# ALX Oncology (ALXO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ALXO
## Company Profile
- Ticker: ALXO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 1.92 USD
- Market cap: 239521992.26 USD
- Last updated: 2026-08-05
## Business Overview
### CD47-Directed Immuno-Oncology
ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells.
### Evorpacept
Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other anticancer medicines. Current development emphasizes HER2-positive cancers and biomarker-selected patients with high CD47 expression.
### ALX2004
ALX2004 is a next-generation clinical candidate that expands the company's innate-immunity pipeline beyond evorpacept and is undergoing initial safety evaluation.
## Why The Stock Is Moving

The latest monitored company update is “ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Initial safety data from the Phase 1 study of ALX2004 in the second half of 2026.
- Topline data from the Phase 2 ASPEN-09-Breast study of evorpacept in mid-2027.

## Drug Assets

- evorpacept

## Recent News
- 2026-08-06 12:00 EST — [ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-second-quarter-2026-financial-results-and-provides-corporat-d99f8edc) — Source: ALX Oncology
- 2026-06-30 20:40 EST — [ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules-b37a2f05) — Source: ALX Oncology
- 2026-06-30 12:00 EST — [ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel](https://biopharmsignal.com/news/ALXO/alx-oncology-appoints-scott-garland-as-chairman-of-the-board-and-michael-listgar-e952538a) — Source: ALX Oncology
- 2026-06-01 12:00 EST — [ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/ALXO/alx-oncology-to-present-at-the-2026-jefferies-global-healthcare-conference-in-new-york) — Source: ALX Oncology
- 2026-05-08 12:00 EST — [ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: ALX Oncology